Alzheimer's test could shape clinical strategies

Athena Neurosciences Inc. has obtained rights to technology that will permit the company to prospectively identify persons at high risk of Alzheimer's disease, which could prove important to the design of clinical trials of therapeutics for the disease.

ATHN last week received an exclusive option to obtain worldwide rights to

Read the full 502 word article

How to gain access

Continue reading with a
two-week free trial.